3rd Quarter - Report

NOVARTIS for NOVARTIS

Firm
Client
Income
—
Expenses
$1,360,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

9 issue areas, each in the filer's own words, with who lobbied on it and where.

Science/Technology SCI

Artificial intelligence

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Manufacturing MAN

H.R. 555, Securing America's Vaccines for Emergencies Act of 2023

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
STACIE AMAN —
TAYLOR BOOTH —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
COURTNEY PIRON —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 555 (118th)

Budget/Appropriations BUD

Advanced Research Projects Agency for Health (ARPA-H) Biosimilars Drug Pricing Fiscal year 2024 Appropriations H.R. 5376, Inflation Reduction Act Importation National Defense Authorization Act FY 2024 Value of Medicine CBO modeling

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SEEMIN PASHA —
COURTNEY PIRON —

Contacted: SENATE; Congressional Budget Office (CBO); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); White House Office

Bills named: H.R. 5376 (118th)

Copyright/Patent/Trademark CPT

Antitrust Legislation Bayh-Dole Act Biopharmaceutical Intellectual Property Biosimilars Compulsory licenses Data Exclusivity H.R. 2883/S. 148, Stop Stalling Access to Affordable Medications H.R. 2884/S. 150, the Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act H.R. 2891/S. 142, the Preserve Access to Affordable Generics and Biosimilars Act H.R. 5376, Inflation Reduction Act S. 79, Patent Coordination and Improvement Act of 2023 S. 113, Prescription Pricing for the People Act of 2023 S. 1128, Ensuring Access to Generic Medications Act (use patents) Intellectual Property Issues in Response to coronavirus Patents Reasonable Pricing Clause Section 101 WTO TRIPS Waiver March-In Rights H.R. 3858/S.1834: A bill to prohibit the President from negotiating or concluding any withdrawal, suspension, waiver, or modification to the Agreement on Trade-Related Aspects of Intellectual Property Rights without explicit authorization from Congress. Restrictions on Intellectual Property Rights Artificial Intelligence Affordable Prescriptions for Patients Act---CLEAR Patents Act Protecting Consumer Access to Generic Drugs Act

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SEEMIN PASHA —
COURTNEY PIRON —

Contacted: Patent & Trademark Office (PTO); SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 142 (118th), S. 1128 (118th), H.R. 2883 (118th), S. 148 (118th), H.R. 3858 (118th), S. 1834 (118th), H.R. 5376 (118th), H.R. 2884 (118th), S. 113 (118th), S. 150 (118th), S. 79 (118th), H.R. 2891 (118th)

Health Issues HCR

340B Drug Discount Program H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. H.R. 2534, PROTECT 340B Act of 2023 340B Contract Pharmacy Policy S. 1133, 340B Accountability Act Accelerated Approval Advanced Research Projects Agency for Health (ARPA-H) Alternative Funding Programs Biosimilar approval and reimbursement policy issues Buy American Executive Order Cancer Moonshot Cell, gene and radioligand therapies Co-pay accumulator programs Diversity in Clinical Trials Drug cost and pricing policy issues Drug Importation and counterfeiting policy issues Drug shortages policy issues FDA modernization policy issues Foreign manufacturing policy issues Genetically Targeted Technologies H.R. 2534, Preserving Rules Ordered for the Entities Covered Through (PROTECT) 340B Act H.R. 2679, Pharmacy Benefits Manager Accountability Act H.R. 5376, Inflation Reduction Act H.R. 4822, Health Care Price Transparency Act of 2023 Inflation Reduction Act Implementation H.R. 5416, The Give Kids a Chance Act The Medicaid VBPs for Patients (MVP) Act H.R. 830/S. 1375, HELP Co-pays Act H.R. 1613, The Drug Price Transparency in Medicaid Act H.R. 198, Drug Pricing Transparency and Accountability Act H.R. 3561, Promoting Access to Treatments and Increasing Extremely Needed Transparency Medicaid Payment Reform Notice of Benefit Payment Parameters (NBPP) Orphan drug policy issues Outcomes based contracting/value based arrangements Patient assistance program policy issues PDUFA, BSUFA, GDUFA Pharmaceutical quality Pharmaceutical supply chain Pharmacy benefit manager policy issues Priority Review Voucher (PRV) Reauthorization of PAHPA Regulatory efficiencies policy issues S. 652/H.R. 2630, Safe Step Act S. 79/H.R. 1717, Interagency Patent Coordination and Improvement Act of 2023 S. 2837, 340B Accountability Act 2021 S. 476/HR. 5567 The Maintaining Investments in New Innovations (MINI) Act H.R. 5539, ORPHAN Cures Act S. 1246, SMART Prices Act S. 127, The Pharmacy Benefit Manager Transparency Act of 2023 S. 1339, Pharmacy Benefit Manager Reform Act S. 1542, Delinking Reveue from Unfair Gouging (DRUG) Act S. 1967, Patients Before Middlemen Act S. 2973 Modernizing and Ensuring PBM Accountability (MEPA) Act H.R. 5378, Lower Costs, More Transparency Act H.R. 2880, Protecting Patients Against PBM Abuses Act Step Therapy Transparency policy issues Utilization management issues Health industry vertical integration CBO modeling 340B Program Implementation & Oversight 340B Accountability Act S. 1182: The 340B Reporting and Accountability Act H.R.2534: PROTECT 340B Act of 2023 H.R.2408: Access to Innovative Treatments Act of 2023 H.R.1790: Biologics Competition Act of 2023 S.113: Prescription Pricing for the People Act of 2023 S.150: Affordable Prescriptions for Patients Act of 2023 Drug Benefit Design

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
STACIE AMAN New —
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SEEMIN PASHA —
COURTNEY PIRON —

Contacted: White House Office; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Congressional Budget Office (CBO); Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 1967 (118th), S. 1246 (118th), H.R. 2679 (118th), H.R. 5539 (118th), S. 1375 (118th), H.R. 5416 (118th), S. 652 (118th), S. 476 (118th), H.R. 2630 (118th), H.R. 5376 (118th), H.R. 2534 (118th), H.R. 5378 (118th), S. 150 (118th), H.R. 198 (118th), H.R. 2408 (118th), S. 1133 (118th), S. 127 (118th), H.R. 1717 (118th), H.R. 2880 (118th), S. 2973 (118th), S. 1339 (118th), S. 1542 (118th), H.R. 3290 (118th), S. 79 (118th), H.R. 830 (118th), S. 1182 (118th), H.R. 1790 (118th), S. 113 (118th), H.R. 5567 (118th), H.R. 1613 (118th), H.R. 4822 (118th), H.R. 3561 (118th), S. 2837 (118th)

Medicare/Medicaid MMM

Anti-Kickback Statute policy issues ASP reporting policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues Drug Pricing H.R. 1613/S. 1038, Drug Price Transparency in Medicaid Act of 2023 H.R. 5376, Inflation Reduction Act H.R. 2666, Medicaid for VBPs for Patients (MVP) Act H.R. 2880, Protecting Patients Against PBM Abuses Act H.R. 3285, Fairness for Patient Medications Act S. 1967, Patients Before Middlemen Act S. 2973 Modernizing and Ensuring PBM Accountability (MEPA) Act H.R. 3561, Promoting Access to Treatments and Increasing Extremely Needed Transparency Innovative Pharmaceuticals (including cell, gene and radioligand therapies), Biosimilars and Generics Inflation Reduction Act Impact on Innovative Pharmaceuticals Medicaid Medicaid rebates and waiver policy issues Medicare Part A, B and D Medicare Part D Negotiations Medicare Part D Re-design and out of pocket cap Outcomes based Contracting/value based arrangements Patient Cost-Sharing and Smoothing Reimbursement for cell therapy products Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals Transparency policy issues Advanced Safe Testing at Residence Telehealth Act of 2023 S. 2052, Protect Patient Access to Pharmacies Act S. 476/HR. 5567, The Maintaining Investments in New Innovations (MINI) Act H.R. 5539, ORPHAN Cures Act Value-Based Purchasing (VBP) Rule CBO modeling H.R.2139/S.908: Medicare Drug Price Negotiation Act H.R.2148/S.909: Prescription Drug Price Relief Act H.R.5125: Strengthening Innovation in Medicare and Medicaid Act S.127: Pharmacy Benefit Manager Transparency Act of 2023 S.142: Preserve Access to Affordable Generics and Biosimilars Act S.150: Affordable Prescriptions for Patients Act of 2023 S.775: Increasing Transparency in Generic Drug Applications Act S.1067: Ensuring Timely Access to Generics of 2023 COVID-19 Pricing-Related Provisions National Coverage Determination Alternative Payment Arrangements for Gene Therapies Average Manufacturer Price Calculations Medicaid Drug Rebate Program Rule (MDRP) Medicare Part B Physician-Administered Products National Coverage Determination Patient Cost-Sharing and Smoothing Protected Classes Support of Patient Premiums and Cost-Sharing Obligations Value-based Contracting and Communications

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
STACIE AMAN New —
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SEEMIN PASHA —
COURTNEY PIRON —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); Congressional Budget Office (CBO); White House Office; SENATE; Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS)

Bills named: S. 2973 (118th), H.R. 2666 (118th), S. 775 (118th), S. 1067 (118th), H.R. 2148 (118th), H.R. 3285 (118th), H.R. 5125 (118th), S. 1967 (118th), H.R. 5567 (118th), H.R. 2139 (118th), S. 908 (118th), S. 127 (118th), H.R. 3561 (118th), S. 909 (118th), S. 142 (118th), H.R. 5376 (118th), H.R. 5539 (118th), S. 2052 (118th), S. 150 (118th), H.R. 2880 (118th), S. 476 (118th), S. 1038 (118th), H.R. 1613 (118th)

Taxation/Internal Revenue Code TAX

Base Erosion Anti-Abuse Tax (BEAT) OECD Digital Tax Orphan Drug Tax Pharmaceutical supply chain incentives R&D Amortization Restrict deductions of excessive interest of members of financial reporting groups for disproportionate borrowing in the United States (Sec. 163(n) & 163(o)) Stopping Harmful Inversions and Ending Low-Tax Developments (SHIELD) Tax Treaties U.S. Corporate Tax OECD Pillar Two H.R.2673: American Innovation and R&D Competitiveness Act S.866: American Innovation and Jobs Act

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SEEMIN PASHA —
COURTNEY PIRON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2673 (118th), S. 866 (118th)

Trade (domestic/foreign) TRD

Access to Medicines Issues Biopharmaceutical Innovation Policies Free Trade Agreements - Intellectual Property and Transparency Provisions Global Health Issues India, China and Canada IP and Market Access Issues International Market Access and Intellectual Property Issues Pharmaceutical Supply Chain Pricing and reimbursement policy issues Quality of Medicines Regulatory Cooperation Supply chain and China Task Force policy issues Tariffs Trade Policy US Swiss Trade Relations US Switzerland Mutual Recognition Agreement on GMP WTO IP Waiver General Patent Reform TRIPS Waiver

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
TAYLOR BOOTH —
NORA CONNORS —
LEO A FARBER —
COURTNEY LEE-ASHLEY —
JOSEPH MCGOWAN —
SEEMIN PASHA —
COURTNEY PIRON —

Contacted: U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); White House Office; Executive Office of the President (EOP); State, Dept of (DOS); SENATE; Commerce, Dept of (DOC); U.S. Agency for International Development (USAID)

Labor Issues/Antitrust/Workplace LBR

Anti-Trust Reform Non-competes Federal Trade Commission's Non-Compete Clause Proposed Rule

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
LEO A FARBER —
JOSEPH MCGOWAN —
COURTNEY PIRON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.